The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse A Non-Interventional Study of Postoperative Treatment With Goserelin Acetate (Zoladex) in Moderate to Severe Endometriosis Patient
- collapse A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared with Tamoxifen in Adjuvant Therapy in Postmenopausal Women with Hormone Receptor+ Early Breast Cancer.
- collapse A Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous Infusions of AZD9773 (CytoFab™) in Japanese Patients with Severe Sepsis and/or Septic Shock
- collapse A Placebo-controlled, Double-blind, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients With Severe Sepsis
- collapse Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimens
- collapse PATTERNS OF CARE IN HORMONE-RECEPTOR POSITIVE, ADVANCED BREAST CANCER
- collapse A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and preliminary efficacy of Tor Kinase Inhibitor (AZD8055) in Asian Patients with Advanced Stage Hepatocellular Carcinoma (HCC) and with Mild or Moderate Hepatic Impairment
- collapse A Phase II Open label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin alone in Patients with Platinum Sensitive Advanced Serous Ovarian Cancer
- collapse Phase II, Randomised, double-blind, two-arm, parallel study of Vandetanib (ZACTIMA , ZD6474) plus Gemcitabine (Gemzar ) or Gemcitabine plus Placebo as first line treatment of advanced (stage IIIB or IV) Non Small Cell Lung Cancer (NSCLC) Elderly patients.
- collapse Open label, phase I ZD6474 head and neck cancer study (FDMA113 short study title).
